Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

NVAX trade ideas

2020 top % NVAX, NIO, TSLA, MCRB, SPWR, ZM, ETH & BTC2020 top % NVAX, NIO, TSLA, MCRB, SPWR, ZM, ETH & BTC Just to think Bitcoin didn’t gain as much % as I imagined before I did this comparison. It makes me wonder that amazingly Bitcoin has a whole lot more upside potential in 2021?! And I still can't believe I got NVAX for $4.64 in July 2019 only to sell it for $16 in April 2020. lol Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny a day for a month it = $5,368,709. Good luck and happy trading friends... *3x lucky 7s of trading* 7pt Trading compass: Price action, entry/exit Volume average/direction Trend, patterns, momentum Newsworthy current events Revenue Earnings Balance sheet 7 Common mistakes: +5% portfolio trades, risk management Beware of analysts motives Emotions & Opinions FOMO : bad timing Lack of planning & discipline Forgetting restraint Obdurate repetitive errors, no adaptation 7 Important tools: Trading View app!, Brokerage UI Accurate indicators & settings Wide screen monitor/s Trading log (pencil & graph paper) Big organized desk Reading books, playing chess Sorted watch-list Checkout my indicators: Fibonacci VIP - volume Fibonacci MA7 - price pi RSI - trend momentum TTC - trend channel www.tradingview.com
NASDAQ:NVAX
by Options360
6
Vaccine raceThe big stories in the new year, though, could come from vaccines that haven't made it to market yet. It's possible that the stocks of the companies developing these experimental vaccines will deliver tremendous gains over the next 12 months. Here are four coronavirus stocks that are especially poised to soar in 2021. Of course, they are could be very volatile and uncertain because of the licencing. They are in phase 2 or 3. Innovio(INO) a small-cap company. It maybe has found its bottom and their vaccine has an advantage in that the drug does not need to be frozen, also announced it entered into a collaborative agreement with Chinese company Advaccine Biopharmaceuticals Suzhou. Their vaccine(INO-4800) could be brought to market within Greater China. Inovio's stock could become a great buy if INO-4800 is successful and the Food and Drug Administration (FDA) approves the vaccine. But the problem is that's not a guarantee. Altimmun(ALT) a small-cap company. Altimmun could regain the high of summer and something getting started. Their vaccine only requires a single dose. It can be stored at room temperature for extended periods. Vaxart(VXRT) is a small-cap company. Found its bottom in a sideways consolidation and now something makes investor interested by the last day momentum. Their vaccine could be really cool because It's a single-dose tablet instead of an injection. That makes Vaxart's vaccine more convenient to take and to distribute and store. Novavax(Nvax) is a mid-cap company. Novavax has a COVID-19/flu combo vaccine. It makes me interested in and I like the sideways consolidation last month or more. Now I waiting for an upward break and it could reach a high of 200 or more. These forecasts were created to support you, but you have to make your trading decisions independently! Which one could be the winner or loser? Who knows? As nobody sees the future, I recommend you that always apply risk management during your trading and highly recommend the diversification!
NASDAQ:NVAXLong
by MoodandMarkets
2
$NVAXNovavax, Inc. (NASDAQ:NVAX) closed the Friday session strong right near the high of the day. I think this stock could see $150 next week. Last night after the market's close, the company announced that it has finalized an agreement with the Government of Canada to supply up to 76M doses of NVX-CoV2373, the company's recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52M doses of the vaccine with the option for up to an additional 24M doses. NVX-CoV2373 is currently in Phase 3 clinical development for the prevention of COVID-19. The company expects to supply NVX-CoV2373 to Canada beginning as early as the second quarter of 2021, following authorization by Canada's regulatory agency. Looking at the daily technical daily chart the near-term outlook is positive. Momentum indicators are starting to point up, which is a sign of growing strength in the stock and MACD is also giving a positive indication. NVAX will move quickly, so keep it on your screen on Monday.
NASDAQ:NVAXLong
by SmoothJB
NOVAVAXif market keep is bullish euphorique structure, we are close to start the 3 wave that is extensive. fundamental: with covid trubbles and vaccination approval we can see that the probable futur trend will be bullish. investor tend to go with hot stocks or easy to guest safe heaven sector, in the case of a global pendemie the one industry that cannot suffer from this is the medical and pharmacetical ones. therfore the probability of a 3 wave arround the corner is really high. also the wave 2 bounce from the 0.618 golden fib ratio, and wave 2 and 4 tend way more that just often to bounce from fib retracement. guessing a probal wave three from past support and resistance and using again the 0.618 to se were wave 4 should bounce at we have a strong probability to succes this trade. as we know fib retracement tend to magicaly worked as resistance and support since so many investor/trader have orders at those levels. entering now in the trade give you a stop loss at 80 so that would be 47 dollar risk/per share to a potential 120 dollar reward/ per share. i don't know about you but i lile those kind of 3:1 reward to risk ratio. best regards, patryck trader at richmonstocks funds.
NASDAQ:NVAXLong
by RICHMONSTOCK
ABC BullishPossible long entry at 123.45 but does not get price over the possible rectangle that is forming..131.50ish with an uptrend would get you past it. I guess if you like this one, basically long entry level is what you are comfy with. Can be Volatile so it could shoot out and up tomorrow! (Today is Sunday..lol) Was looking like a flag but flag looking a bit heavy for pole at this point.. Price looks to be fighting hard to break through the resistance and looks like WW2 inside of there! It appears price will either break through or bounce back down very soon. Just looks that way but who knows? I am not in this but someone asked me to look at it. If price gets through that channel, I do think targets may be met. Not a recommendation
NASDAQ:NVAX
by lauralea
NVAX Long into final clinical trials NVAX has received a total of $2.4b in outside funding (gov't and private) which is one of the largest amounts received by the companies involved in Operation Warp Speed. Published vaccine results which few of the companies have made public show the highest amount of vaccine antibody counts (www.nytimes.com) Novavax has also reinvested those funds and has an estimated 2 billion dose capacity by 2021 (ir.novavax.com). Now entering the last phase of their clinical trails with 10,000 participants in the UK if the trail continues to push forward and publishes promising results expect this to run very hard past the previous ATH of $189 Good trade would be continue to acquire $100-$105 range or enter on breakout above $120 with a Stoploss at $94 Hope for a pull back and enter on the golden pocket of $68-75 Long term this company has positive prospects for NanoFlu as well This trade is active Assistance for EW analysis from Butch KillTrigger
NASDAQ:NVAXLong
by Binglex2